RecruitingPhase 2NCT06066346

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

17 participants

Start Date

Sep 27, 2023

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether talquetamab — a drug that activates the immune system to attack myeloma cells — can help prevent multiple myeloma from coming back in patients who recently received CAR-T cell therapy (ide-cel) and are currently in remission or near-remission. **You may be eligible if...** - You have multiple myeloma and have been treated with ide-cel CAR-T cell therapy 1–3 months ago - You previously received an immunomodulatory drug (IMiD), a proteasome inhibitor, and a CD38 antibody - Your myeloma markers (protein levels) are very low after CAR-T therapy - There is no sign of disease progression - You are 18 or older with a good performance status (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has progressed since CAR-T therapy - You have ongoing cytokine release syndrome or serious neurotoxicity from CAR-T - It has been less than 1 month or more than 3 months since your CAR-T infusion Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.